AstraZeneca Plc said on Monday it began to enroll 30,000 participants aged above 18 in a late-stage study to evaluate its COVID-19 vaccine candidate, AZD1222.
Participants are being randomized to receive two doses of either AZD1222 or a saline control, four weeks apart, with twice as many participants receiving the potential vaccine as the saline control, the company said.
The study is being funded by the U.S. government, the London-listed company said.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .
<!– Please implement on Entertainment only, remove the twitter handle after the byline in #byline_share
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.
For feedback, complaints, or inquiries, contact us.